ArticleJournal of Cancer2018

Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials.

Yu-Tuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.